Literature DB >> 22661053

Association of hypermobility and ingrown nails.

Fatma Gulru Erdogan1, Abdurrahman Tufan, Munevver Guven, Berna Goker, Aysel Gurler.   

Abstract

Ingrown nail (onychocryptosis) is a common condition with severe pain and various associated morbidities. Although some underlying factors are identified, its etiology remains largely unknown. Generalized joint hypermobility (GJH) is a common entity with clinical features that might prone affected individuals to ingrown nails. Herein, we investigated the incidence of GJH in patients with ingrown nails to determine possible association between hypermobility and ingrown nail formation. Patients 16-50 years of age who were undergoing treatment for ingrown nails at the dermatology clinic were consecutively enrolled into the study. Patients with known rheumatic diseases or orthopedic foot disorders were excluded. All patients were in a pain-free period at the time of examination. The control group was comprised of age- and sex-matched healthy subjects without a history of ingrown nail. Assessment of GJH was made according to Beighton criteria. Local hypermobility was evaluated by measurement of range of motion using a goniometer. Thirty-nine patients (male/female, 17/22, mean age 31.9 ± 11.3 years) and 32 healthy subjects (male/female 12/20, mean age 31.7 ± 10.4 years) were included. Patients with ingrown toe nails were more likely to have GJH compared to healthy subjects (35.9 vs. 9.4 %, p = 0.009). Toes with ingrown nails had significantly smaller maximum dorsiflexion angles (p < 0.001) compared to toes of healthy subjects. Ingrown nail formation may be associated with GJH. However, when examined locally, there is a limited range of motion in the affected toe rather than hypermobility, which could be due to the degenerative process facilitated by the hypermobility.

Entities:  

Mesh:

Year:  2012        PMID: 22661053     DOI: 10.1007/s10067-012-2014-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  "Ingrown" nails and other toenail problems--surgical treatment.

Authors:  M W JOHNSTONE
Journal:  Calif Med       Date:  1962-10

2.  New method alternative to surgery for ingrown nail: angle correction technique.

Authors:  Burhan Ozdil; Ismail Cem Eray
Journal:  Dermatol Surg       Date:  2009-04-09       Impact factor: 3.398

3.  Joint hypermobility syndrome.

Authors:  Juliette Ross; Rodney Grahame
Journal:  BMJ       Date:  2011-01-20

4.  Risk factors in onychocryptosis.

Authors:  D T Langford; C Burke; K Robertson
Journal:  Br J Surg       Date:  1989-01       Impact factor: 6.939

5.  Association of abnormal foot angles and onychocryptosis.

Authors:  Fayeq M Darwish; Waleed Haddad; Fouad Ammari; Ziad Aoudat
Journal:  Foot (Edinb)       Date:  2008-07-01

Review 6.  Joint hypermobility.

Authors:  Howard A Bird
Journal:  Musculoskeletal Care       Date:  2007-03

7.  Generalized joint laxity associated with increased medial foot loading in female athletes.

Authors:  Kim D Barber Foss; Kevin R Ford; Gregory D Myer; Timothy E Hewett
Journal:  J Athl Train       Date:  2009 Jul-Aug       Impact factor: 2.860

Review 8.  Hallux rigidus: etiology, biomechanics, and nonoperative treatment.

Authors:  Paul S Shurnas
Journal:  Foot Ankle Clin       Date:  2009-03       Impact factor: 1.653

9.  Hallux rigidus: A case report of successful chiropractic management and review of the literature.

Authors:  Deepak B Manral
Journal:  J Chiropr Med       Date:  2004

10.  Hypermobility and the hypermobility syndrome, part 2: assessment and management of hypermobility syndrome: illustrated via case studies.

Authors:  Jane V Simmonds; Rosemary J Keer
Journal:  Man Ther       Date:  2008-01-24
View more
  1 in total

Review 1.  Interrater and Intrarater Reliability of the Beighton Score: A Systematic Review.

Authors:  Lauren N Bockhorn; Angelina M Vera; David Dong; Domenica A Delgado; Kevin E Varner; Joshua D Harris
Journal:  Orthop J Sports Med       Date:  2021-01-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.